GlassScriptPhysician profile
Charles Bensenhaver
NPI 1215031646
$780.00
in general payments reported to CMS, 2019-2025
16 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $96.01 · 2021: $39.81 · 2022: $30.24 · 2023: $73.75 · 2024: $134 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $157.87 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $124.74 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $109.44 | 2019-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $94.92 | 2021-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $83.51 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $29.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.93 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $26.59 | 2019 | |
| Neos Therapeutics, LP | $26.50 | 2020 | |
| Alkermes, INC. | $16.00 | 2025 | Lybalvi |
| Indivior INC. | $15.48 | 2022 | |
| Eisai INC. | $15.28 | 2020 | |
| Lundbeck LLC | $14.67 | 2025 | Rexulti |
| Tempus Ai, INC | $14.11 | 2024 | |
| Acadia Pharmaceuticals INC | $11.42 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bensenhaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.